AstraZeneca generated $275m in revenue from its non-profit Covid-19 vaccine in the first quarter, while sales of cancer drugs and growth in emerging markets helped the drugmaker beat earnings and sales expectations.
The pharmaceutical company confirmed its full-year forecasts of revenue increasing by a low-teens percentage, with core earnings per share rising faster, to between $4.75 and $5.
Pascal Soriot, AstraZeneca’s chief executive, said the strong performance was despite the pandemic delaying the diagnosis and treatment of many conditions.
“We delivered solid progress in the first quarter of 2021 and continued to advance our portfolio of life-changing medicines,” he said. “We expect the impact of Covid to reduce and anticipate a performance acceleration in the second half of 2021.”
AstraZeneca reported revenue of $7.3bn, excluding the contribution from the vaccine it developed with the University of Oxford, up 15 per cent year-on-year and higher than the consensus forecast for $7bn.
Oncology sales increased by 20 per cent from the same period the year before, while revenue from emerging markets was up 14 per cent, with a 19 per cent increase in China.
Core earnings per share soared 55 per cent to $1.63, beating the average analyst estimate of $1.48.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
